Status:
RECRUITING
High Dose Oral Omeprazole in High Risk UGIB
Lead Sponsor:
King Chulalongkorn Memorial Hospital
Conditions:
GI Bleeding
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world. After endoscopic treatment, proton pump inhibitor (PPI) is recommended to prevent re-bleeding. ...
Eligibility Criteria
Inclusion
- Patients with peptic ulcer bleeding and endoscopic finding show ulcer with Forrest classification Ia (spurting haemorrhage), IIa (oozing haemorrhage), Ib (non-bleeding visible vessel)
- Age \> 18 years old
Exclusion
- Deny to participate
- Pregnancy or lactation
- Low risk peptic ulcer bleeding including clean base ulcer, flat pigmented spot
- Non-peptic ulcer bleeding eg. erosive gastritis/duodenitis, Mallory Weiss tear, esophageal/gastric/duodenal varices, vascular lesions (eg. Dieulafoy) , malignant ulcer
- Bleeding tendency
- Terminal stage of cancer
- ESRD on hemodialysis
- Decompensated liver cirrhosis
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT04394663
Start Date
October 1 2020
End Date
December 31 2025
Last Update
September 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
King Chulalongkorn Memorial Hospital
Pathum Wan, Bangkok, Thailand, 10330
2
Surin Hospital
Surin, Thailand, 32000